Introduction
The prognosis of ALL in children has improved significantly with the use of modern therapeutic protocols. Currently, about 80% of children with ALL are cured with chemotherapy alone. 1, 2 Haematopoietic stem cell transplantations (HSCT) from a matched sibling donor (MSD) cures more than 50% of children who failed first-line chemotherapy. [3] [4] [5] However, 70% of patients who might benefit from this therapy lack an HLA MSD, 6 and HLA polymorphism is still a major obstacle in finding a fully matched, unrelated donor (UD) for 40% of the patients for whom the search for a UD is activated. [7] [8] [9] Therefore, several institutions have recently explored alternative sources for HSCT, such as HLA partially mismatched, unrelated or related donors, 10 and other sources of stem cells, such as umbilical cord blood (UCB) cells, [11] [12] [13] [14] or G-CSF mobilized T-cell-depleted peripheral blood haematopoietic stem cells provided by related haploidentical donors. 15, 16 Indications for auto-HSCT are limited to a small subset of children with either late marrow relapse or extramedullary recurrence. 17, 18 A recent survey by the European Bone Marrow Transplant group showed that prior to May 1996, the majority of allografts (70%) were performed from HLA MSDs. During the last 10 years, the number of alternative HSCTs, including UDs, partially matched family donor and UCB HSCTs, has increased significantly (P ¼ o0.0001) and reached 61% of the allografts carried out between 1999 and 2002 ( Figure 1 ). 19 In this paper, we provide practical guidelines to help define an algorithm for the treatment of children relapsing during or after first-line chemotherapy for ALL.
Donor selection
When a child is eligible for HSCT, HLA typing of the patient, of the parents and of siblings must be performed. HLA-A, -B and -C antigens (Ags) must be identified by median resolution, while HLA-DR Ags and HLA-DQ Ags must be typed by high-resolution methods. If an MSD or a phenotypically matched relative is available, the patient should proceed to transplant in accordance with the chemotherapy protocol. If the patient qualifies for matched or mismatched donor transplantation, HLA typing by high resolution and a simultaneous search for a UD and a UCB should be initiated. Searches for UDs are processed through Bone Marrow Donors World Wide (BMDW), a network that includes more than 11 million volunteer UDs enrolled in 58 registries, while searches for UCB units are processed either through Netcord, which includes 130 000 CB units in 22 banks, or through BMDW, which includes 261 000 CB units in 36 banks.
The choice
Several factors influence the donor choice: disease status and response to chemotherapy, HLA matching, the availability of a donor and other characteristics of the identified donor and the recipient, and the outcome of the various options as reported in the literature. This study focuses mainly on the effect of the mentioned factors on survival. The effect on specific outcomes, such as graft failure and the incidence of acute and chronic GvHD, should not be the primary goal of donor selection, but it should help us to assign a specific risk-adapted treatment strategy to the recipient.
HLA typing
Since 1990, a technological revolution has taken place in tissue typing methods, spanning from the use of serology to define HLA Ags to the modern DNA era. Currently, single nucleotide differences between two unique HLA alleles of the same Ag can be detected using PCR-based techniques. 20 Two levels of DNA-based HLA matching may be identified: donors and recipients are considered highresolution (allele level) matched for a given locus when their high-resolution typing is identical, indicating that they express an identical allele (four digits). Donors and recipients are considered low-resolution (serology or Ag level) matched for a given locus when DNA-typing assignment of the first two digit alleles for a given locus is identical.
Matching criteria
A low-resolution mismatch can be detected using low/ intermediate-resolution typing, whereas a high-resolution mismatch can only be detected by using high-resolution typing techniques. A high-resolution mismatch indicates that the donor and the recipient may be matched at the serologic or low level of resolution but that they may differ with regard to the specific allele they express from within that serologic or low-resolution antigenic family. Transplants are classified as HLA mismatched with one, two, three, four or five differences depending on whether disparities are detected in HLA-A, HLA-B, HLA-C or HLA-DRB1, and -DQB1 Ags or alleles. When a fully matched donor is not available, a subset of HLA disparities of little clinical relevance must be selected. Conflicting results have been reported on the relative importance of various class I and II loci mismatches on outcome. [21] [22] [23] [24] [25] [26] [27] [28] Early studies reported that low-resolution mismatches at HLA-A and -B Ags, and high-resolution mismatches at HLA-DRB1 allele are associated with worse GvHD and survival. [21] [22] Matching algorithms favoured class II matching over class I matching when a complete match could not be found. In this group, which is often described as 'six Ag matched', additional mismatches for HLA-DQ and -DP had no impact on survival. [23] [24] [25] Linkage disequilibrium between the DR and DQ loci may have contributed to this observation. A single-centre study of donor-recipient pairs suggested that when patients have a choice of equivalently matched donors, choosing an HLA-DQB1-matched donor over a mismatched donor may decrease post-transplant complications. 26 In this large study, a single HLA class I or II allele mismatch had no influence on survival, while multiple mismatching for more than one class I allele and simultaneous disparities in class I and II alleles increased the mortality rate. With regard to HLA-DP matching, Ringden et al. 27 reported observing a positive impact on outcome. In fact, additional benefits may be reaped by matching HLA-DQB1 and -DPB1 in patients who have several highly matched suitable donors. In contrast, other reports showed that HLA-DP alloAgs can provide the stimulus for graft-versus-leukaemia in a large population of HLA-A, -B, -C, -DRB1 and -DQB1 allele-identical, unrelated transplant recipients. Statistically, relapse was significantly higher among HLA-DPB1-matched patients (74%) as compared with HLA-DPB1-mismatched patients (56%, P ¼ 0.001). 28 A large National Marrow Donor Program (NMDP) study reported that single low-resolution mismatches for both class I (including HLA-C) and for DRB1 loci are independently associated with a significantly higher risk of graft rejection, GvHD and mortality, as compared with full matching. This observation suggests that HLA-C typing should be included in search algorithms. 25 These risks increase as the number of multiple HLA mismatches increases, and thus choosing the donor with the fewest mismatches may reduce complications. The risk of grades III-IV acute GvHD that is associated with low-resolution detectable mismatches is similar to the risk in highresolution mismatches. However, transplants with lowresolution mismatches are associated with significantly worse survival than those with only high-resolution mismatches. 25 Therefore, choosing donors with highresolution mismatches over those with low-resolution mismatches may lower post-transplant complications. The same paper showed that high-resolution mismatching, particularly at HLA-A and -DRB1, is associated with increased mortality. A single allele-level mismatch at HLA-A, -B, -C or -DRB1 is associated with an 8-12% reduction in survival at 5 years, with trends indicating that survival worsened as the number of allelic mismatches increased.
In detail, allele mismatches at HLA-A and -DR showed negative trends on survival. 25 Some transplant centres select their donors based on high-resolution typing for HLA-A, -B, -C and -DR and, whenever possible, prefer to match 8/8 HLA alleles; other institutions prefer to match 10/10 HLA alleles and accept not more than one mismatch. Currently, we are able to find an HLA-A, -B and -DR matched donor in the BMDW registry for 86% of the patients, and 74% of the donor phenotypes occur X4 times. Research is currently focused on identifying other permissible HLA mismatches that might benefit the majority of patients who lack an HLAmatched UD. HLA allele sequencing has recently opened a new debate over whether multiple amino acid substitutions are less permissive than fewer substitutions. It must be highlighted that the increasing amount of typing information that is acquired from high resolution should not be used to exclude more patients from the potentially curative benefits of HSCT, but rather that it should be used to stratify the patients' risk and to adapt treatment strategies to more complete and precise matching information.
Disease phase
Overall transplant success is highly influenced by the disease status at transplant. Although the availability of a well-matched donor is associated with improved overall survival, the major limiting factor for successful UD HSCT occurs when patients with rare phenotypes relapse while the search is still ongoing. 7 A recent analysis by the International Histocompatibility Working Group in haematopoietic cell transplantation showed an increased risk of death among low-risk patients with single HLA mismatches, although these were well tolerated among higherrisk patients. When analysed by locus, HLA-B and -C mismatches conferred increased risk among low-risk patients. These results suggest that not all HLA loci contribute to equivalent risk. 29 Other factors influencing transplant outcome The optimal strategy for selecting a UD is currently controversial. Transplant teams often prefer donors who are CMV seronegative for seronegative patient, CMV-IgGpositive donors for CMV-positive patients, younger than other potential donors, male gender or nulliparous females for male patients and ABO group-compatible with the patient. Priority may also be given to a more robust donor if there is concern about obtaining an adequate number of stem cells.
CMV and human herpes virus (HHV) status. CMV serology of both the donor and the recipient, as well as the type of donor and thus the consequent HSCT procedure, are all closely linked in determining the risk of CMV reactivation or disease and death resulting from CMV or other transplant-related complications. The probability of developing CMV disease after allogeneic transplant is 5% for seronegative patients with seropositive donors, 14% for seropositive patients with seronegative donors and 12% for seropositive patients with seropositive donors. 30 In another study, multivariate analysis showed that poor leukaemia-free survival is associated with CMV-seronegative grafts to CMV-seropositive recipients. 27 These results were not confirmed by a recent study that detected no adverse effects of donor and recipient CMV serology status on survival, GvHD, engraftment or relapse. 31 The preemptive use of drugs such as ganciclovir and CMV-specific T cells might contribute to preventing CMV infections in recipients who are at risk.
Donor age. In a large, single-centre study, multivariate analysis showed that donor age plays a more important role in better survival and in better disease-free survival 31 than donor CMV serology status, gender, parity, ABO incompatibility and race. This might be due to the fact that there is greater replacement of naive T cells by memory T cells as age increases, thus leading to decreased tolerance, as the immune system is exposed to a greater variety of foreign Ags 32 or to decreased marrow cellularity over time.
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Donor gender. Priority is usually given to male donors because of their larger size and because of the increase in GvHD that is associated with female donors. In adults, studies involving HLA MSDs confirmed the increased incidence of acute and chronic GvHD with female or multiparous donors, especially when the recipient is a male. 34 These data were not confirmed in multivariate analysis or in studies involving UDs.
A more recent study showed that male donors and nulliparous female donors significantly correlated with a lower probability of chronic GvHD, but did not impact disease-free survival. 31 ABO compatibility. The impact of ABO group compatibility is controversial. A single-centre study previously identified it as being a factor that is associated with reduced mortality. 35 This observation could be related to the fact that unmodified marrow is associated with the infusion of higher nucleated cell doses, which is in turn predictive of better survival. 36 However, other studies did not confirm that ABO group incompatibility affects outcome. 30, 37 Choice of an UCB Currently, most transplant centres select UCB units based on HLA-A and -B low-resolution typing and HLA-DRB1 high-resolution typing. All reports have shown that cell dose is the most important determinant of survival. In addition, HLA matching does influence outcome, resulting in better survival in better matched recipients. Survival depends on the number of HLA mismatches, though with no differences among zero, one or two HLA mismatches. Three or more Ag mismatches should be avoided. Cell dose and number of HLA mismatches interact mutually on engraftment and outcome. A higher cell dose might partially overcome the negative impact of HLA for each level of HLA disparity. 38 The influence of high-resolution HLA matching is controversial. In a retrospective study, no benefits were observed for high-resolution DNA typing for either HLA class I (HLA-A, -B and -C) or for class II (HLA-DRB1 and -DQB1) loci. 39 Guidelines for a cord blood choice have been published by the Eurocord group. 38 Outcome of various options reported in the literature A summary of the results that have been achieved by various strategies is reported in Table 1 .
Algorithm
A suitably matched donor (8/8 or 10/10 allele matched) can usually be identified within 4-6 weeks for patients with common haplotypes. It may take much longer to identify a donor for less common HLA types. Therefore, alternative treatment options should be offered to these patients with an indication for a mismatch donor transplantation, and a decision should be made as to whether to reduce the matching requirements or to select another therapy, such as UCB, or a partially matched family donor. The strong impact that HLA-A, -B, -C and -DRB1 have on survival and the controversial impact of HLA-DQ and -DP suggest that when mismatching is unavoidable, it is appropriate to accept a mismatch for HLA-DQ or -DP if this facilitates better matching for HLA class I loci and DR. A less than two Ag-mismatched CB unit containing more than 3 Â 10 7 nuclear cells should be considered equivalent to an 8/8 allele-matched UD. 43, 44 The decision should be made based on the urgency of the HSCT. Haploidentical HSCT should be offered if no donors and no CB units with the abovementioned characteristics are available. Some teams consider haploidentical SCT as the second option when an acceptable UD is not available.
Future goals include improving the results of transplants from alternative donors through precise HLA typing, homogeneous donor selection, reducing relapse incidence, shortening GvHD prophylaxis, monitoring minimal residual disease and chimaerism, reducing toxicity and infections through homogeneous supportive care and monitoring viral and fungal infections.
The aim is not to prove that one form of therapy is superior to another, but rather to increase the total number of cured children with second CR ALL.
